GMS | Deutscher Rheumatologiekongress 2024 | The effectiveness of ixekizumab and other bDMARDs at 12-months for patients with PsA in real-world settings: Results from the PRO-SPIRIT study

Table 1: Baseline characteristics and effectiveness of IXE and other bDMARDs at 12-months

gms | German Medical Science